General procedure for the synthesis of the target compounds 11a,b,15a,b. by Ahmed A. Gaber (13302308)

Subjects:

Binding of compound 16 with DNA-Topo II complex. by Ahmed A. Gaber (13302308)

Subjects:

General procedure for the synthesis of the target compounds 16–20. by Ahmed A. Gaber (13302308)

Subjects:

Effect of compound 16 on cell cycle progression in HCT-116 cells after 48h treatment. by Ahmed A. Gaber (13302308)

Subjects:

Effect of compound 16 on stages of the cell death process in HCT-116 cells after 48 h treatment. by Ahmed A. Gaber (13302308)

Subjects:

Effect of compound 16 on the levels of BAX, and Bcl-2 proteins expression in HCT-116 cells treated for48 h. by Ahmed A. Gaber (13302308)

Subjects:

Effect of compound 16 and m-AMSA on relaxation of supercoiled pBS-SK (+) DNA by human recombinant Topo II. by Ahmed A. Gaber (13302308)

Subjects:

General procedures for the synthesis of the key compounds 7a, b, 9, and 10. by Ahmed A. Gaber (13302308)

Subjects:

Binding of compound 11a with DNA-Topo II complex. by Ahmed A. Gaber (13302308)

Subjects:

The contributions of amino acids around 10 Å of the ligand to the binding free energy. by Ahmed A. Gaber (13302308)

Subjects:

ALS patients’ tissues exhibit increased phosphorylation of MARK2. by Yu-Ning Lu (10291271)

“…<p>(<b>A</b>) Representative immunoblot analyses of PKCδ, MARK2-⁵⁹⁵T, and eIF2α in the spinal cord tissues from ALS patients and non-ALS controls, indicating that increased phosphorylation of PKCδ-⁵⁰⁵T, MARK2-⁵⁹⁵T, and eIF2α-⁵¹S is a general phenotype in patient tissues. …”

Deletion of Hhp2 markedly increased Sre1 activity. by Hao Miao (1742044)

“…<p>Deletion of <i>hhp2</i>⁺ gene markedly increased Sre1 activity in the presence/absence of CLZ (2 μg/ml to 8 μg/ml) (A), TER (2 μg/ml to 8 μg/ml) (B) or CoCl₂ (0.08 mM to 0.32 mM) (C). …”

Binding of compound 12b with DNA-Topo II complex. by Ahmed A. Gaber (13302308)

Subjects:

3D interactions between the ligand and the protein_DNA complex in the first (C1) and second (C2) clusters. by Ahmed A. Gaber (13302308)

Subjects:

Binding of amsacrine with DNA-Topo II complex. by Ahmed A. Gaber (13302308)

Subjects:

The center of mass distances between the protein-DNA complex and the ligand (Blue line), and the protein and DNA (red line). by Ahmed A. Gaber (13302308)

Subjects:

Fig 12 - by Ahmed A. Gaber (13302308)

Subjects:

The number of clusters, number of interactions, and their types between the ligand and protein_DNA complex. by Ahmed A. Gaber (13302308)

Subjects:

Binding of compound 17 with DNA-Topo II complex. by Ahmed A. Gaber (13302308)

Subjects:

Fig 4 - by Ahmed A. Gaber (13302308)

Subjects: